CareFusion — Q2 2012 Earnings Presentation
19 slides from CareFusion's earnings presentation, Feb 2, 2012
Slide 1: Q2 and 1H Fiscal 2012 Investor/Analyst Call
Exhibit 99.2 €) CareFusion Q2 and 1H Fiscal 2012 Investor/ Analyst Call February 2, 2012
Slide 2: Forward-Looking Statements, GAAP Reconciliation and New Reporting Segments
Forward-Looking Statements, GAAP Reconciliation and New Reporting Segments “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon
Slide 3: Today's Speakers
Today’s Speakers • Kieran Gallahue, Chairman and Chief Executive Officer • Jim Hinrichs, Chief Financial Officer © 2012 CareFusion Corporation or one of its subsidiaries. All rights reserved. 3
Slide 4: Agenda
Agenda © 2012 CareFusion Corporation or one of its subsidiaries. All rights reserved. 4
Slide 5: Q2 and 1H Fiscal 2012 Results
€) CareFusion Q2andd.H Aiséecatt2012 Resilits
Slide 6: Q2 FY12 Year-Over-Year Quarterly Review
Q2 FY12 Year-Over-Year Quarterly Review GAAP Adjusted $M % Change 1 $M % Change 1 Revenue $915 3% $915 3% 2 Operating Expenses $314 (3)% $307 4% Operating Income 2 $143 17% $150 - % Income From Continuing $95 30% $99 4% Operations 2 Diluted EPS From Continuing $0.42 31% $0.44 5% Operations 2 1 % Cha
Slide 7: Q2 FY12 Year-Over-Year Quarterly Segment Review
Q2 FY12 Year-Over-Year Quarterly Segment Review GAAP Adjusted Medical Systems $M % Change 1 $M % Change 1 Revenues $571 9% $571 9% 2 Segment Profit $121 27% $124 12% Procedural Solutions $M % Change 1 $M % Change 1 Revenues $344 (5)% $344 (5)% 2 Segment Profit $22 (19)% $26 (33)% 1 % Change over pri
Slide 8: Q2 FY12 Year-Over-Year Quarterly Sub-Segment Revenues
Q2 FY12 Year-Over-Year Quarterly Sub-Segment Revenues $ in millions Q2 FY12 Q2 FY11 % Change Medical Systems $571 $523 9% Dispensing Technologies $257 $229 12% Infusion Systems $239 $223 7% Respiratory Technologies $69 $65 6% Other $6 $6 - % Procedural Solutions $344 $363 (5)% Infection Prevention $
Slide 9: 1H FY12 Year-Over-Year Review
1H FY12 Year-Over-Year Review GAAP Adjusted $M % Change 1 $M % Change 1 Revenue $1,759 4% $1,759 4% 2 Operating Expenses $633 (4)% $615 4% 2 Operating Income $251 25% $269 - % Income From Continuing $162 49% $175 10% Operations 2 Diluted EPS From Continuing $0.72 47% $0.78 10% Operations 2 1 % Chang
Slide 10: 1H FY12 Year-Over-Year Segment Review
1H FY12 Year-Over-Year Segment Review GAAP Adjusted Medical Systems $M % Change 1 $M % Change 1 Revenues $1,080 9% $1,080 9% 2 Segment Profit $209 28% $219 9% Procedural Solutions $M % Change 1 $M % Change 1 Revenues $679 (4)% $679 (4)% 2 Segment Profit $42 11% $50 (25)% 1 % Change over prior year p
Slide 11: 1H FY12 Year-Over-Year Sub-Segment Revenues
1H FY12 Year-Over-Year Sub-Segment Revenues $ in millions 1H FY12 1H FY11 % Change Medical Systems $1,080 $991 9% Dispensing Technologies $494 $434 14% Infusion Systems $445 $415 7% Respiratory Technologies $129 $130 (1)% Other $12 $12 - % Procedural Solutions $679 $706 (4)% Infection Prevention $28
Slide 12: Updated Fiscal 2012 Guidance
Updated Fiscal 2012 Guidance
Slide 13: Updated FY12 Financial Guidance
Updated FY12 Financial Guidance February 2, 2012 1 2 Previous FY12 Outlook Updated FY12 Outlook 3-5% growth over FY11 revenue of 3-5% growth over FY11 revenue of Total Revenue $3.5B on a constant currency basis $3.5B on a constant currency basis Adjusted Operating ~18% ~17.1% Margin 3 Adjusted Effec
Slide 14: FY12 Revenue and Adjusted EPS Guidance and Assumptions
FY12 Revenue and Adjusted EPS Guidance and Assumptions • Guidance O Revenue growth of 3 to 5 percent over FY11 revenues of $3.5B on a constant currency basis O Adjusted diluted EPS of $1.75 to $1.85 • Assumptions O CareFusion markets grow low single digits; expect to do better in markets where we ar
Slide 15: FY12 Medical Systems Segment-Related Assumptions vs. FY11 Results
FY12 Medical Systems Segment- Related Assumptions vs. FY11 Results • Revenues grow on a percentage basis by mid to high single digits O Dispensing Technologies: Revenues grow on a percentage basis by low double digits • Assumes contributions from Rowa for approximately 11 months of the year O Infusi
Slide 16: FY12 Procedural Solutions Segment-Related Assumptions vs. FY11 Results
FY12 Procedural Solutions Segment- Related Assumptions vs. FY11 Results • Revenues on a percentage basis are flat to down low single digits O Infection Prevention: Revenues grow on a percentage basis by low to mid single digits O Medical Specialties: Revenues grow on a percentage basis by low to mid
Slide 17: Slide 17
Slide 18: Q2 FY12 Non-GAAP Reconciliations
Q2 FY12 Non-GAAP Reconciliations Q2 FY12 Nonrecurring Q2 FY12 $ in millions 1 1 GAAP Items Adjusted Operating Expenses $314 $(7) $307 Operating Income $143 $7 $150 Income From Continuing Operations $95 $4 $99 Diluted EPS From Continuing $0.42 $0.02 $0.44 Operations 2 Medical Systems Segment Profit $
Slide 19: 1H FY12 Non-GAAP Reconciliations
1H FY12 Non-GAAP Reconciliations 1H FY12 Nonrecurring 1H FY12 $ in millions 1 1 GAAP Items Adjusted Operating Expenses $633 $(18) $615 Operating Income $251 $18 $269 Income From Continuing Operations $162 $13 $175 Diluted EPS From Continuing $0.72 $0.06 $0.78 Operations 2 Medical Systems Segment Pro